Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 6/20 | 1.00 |
| ▸ | MEN1 | O00255 | 5/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 5/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 1.00 |
| ▸ | TP53 | P04637 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | HPGD | P15428 | 3/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 3/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | ALOX12 | P18054 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 4/20 | 0.85 |
| ▸ | NFKB2 | Q00653 | 3/20 | 0.85 |
| ▸ | RELA | Q04206 | 3/20 | 0.85 |
| ▸ | FLT3 | P36888 | 2/20 | 0.83 |
| ▸ | CTSL | P07711 | 2/20 | 0.79 |
| ▸ | MAOB | P27338 | 3/20 | 0.74 |
| ▸ | ACHE | P22303 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL633470 | 1.00 | ABCG2 (1.00) | ABCG2MEN1KMT2ACYP3A4TDP1 | |
| SCHEMBL30383806 | 1.00 | ABCG2 (1.00) | ABCG2MEN1KMT2ACYP3A4TDP1 | |
| SCHEMBL25217986 | 1.00 | ABCG2 (1.00) | ABCG2MEN1KMT2ACYP3A4TDP1 | |
| Ethane SCHEMBL25195312 | 0.99 | ABCG2 (0.97) | ABCG2MEN1KMT2ACYP3A4TDP1 | |
| Homobutein SCHEMBL633521 | 0.92 | MEN1 (1.00) | ABCG2MEN1KMT2ACYP3A4TDP1 | |
| SCHEMBL25206351 | 0.92 | MEN1 (0.85) | ABCG2MEN1KMT2ACYP3A4TDP1 | |
| Homobutein SCHEMBL25190880 | 0.92 | MEN1 (1.00) | ABCG2MEN1KMT2ACYP3A4TDP1 | |
| SCHEMBL633170 | 0.92 | MEN1 (0.85) | ABCG2MEN1KMT2ACYP3A4TDP1 | |
| Homobutein SCHEMBL31028350 | 0.92 | MEN1 (1.00) | ABCG2MEN1KMT2ACYP3A4TDP1 | |
| Homobutein SCHEMBL633522 | 0.92 | MEN1 (1.00) | ABCG2MEN1KMT2ACYP3A4TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4655410-A2 | O-METHYLATION OF PHENOLIC SUBSTANCES VIA FUNGAL O-METHYLTRANSFERASE | Symrise AG (DE) | 2025-12-03 | — | — | EP | claimed |
| WO-2024156359-A1 | O-METHYLATION OF PHENOLIC SUBSTANCES VIA FUNGAL O-METHYLTRANSFERASE | SYMRISE AG (DE) | 2024-08-02 | — | — | WO | claimed |
| WO-2024156879-A2 | O-METHYLATION OF PHENOLIC SUBSTANCES VIA FUNGAL O-METHYLTRANSFERASE | SYMRISE AG (DE) | 2024-08-02 | — | — | WO | claimed |
| EP-1888174-B1 | USE OF CHALCONES FOR THE TREATMENT OF VIRAL DISORDERS | JOHNSON & JOHNSON CONSUMER (US) | 2012-02-22 | — | — | EP | claimed |
| EP-1888174-A1 | USE OF CHALCONES FOR THE TREATMENT OF VIRAL DISORDERS | Johnson and Johnson Consumer Companies, Inc. (US) | 2008-02-20 | — | — | EP | claimed |
| WO-2006127539-A1 | USE OF CHALCONES FOR THE TREATMENT OF VIRAL DISORDERS | JOHNSON & JOHNSON CONSUMER COMPANIES, INC. (US) | 2006-11-30 | — | — | WO | claimed |
| US-20060270614-A1 | Use of chalcones for the treatment of viral disorders | JOHNSON & JOHNSON CONSUMER COMPANIES, INC. | 2006-11-30 | — | — | US | claimed |
| WO-1995006628-A1 | TREATMENT AND PROPHYLAXIS OF DISEASES CAUSED BY PARASITES OR BACTERIA | STATENS SERUMINSTITUT (DK) | 1995-03-09 | — | — | WO | claimed |
| EP-4747367-A1 | NEW ENZYMES FOR THE MANUFACTURING OF 4'-O-METHYLATED PHENOLIC SUBSTANCES | Symrise AG (DE) | 2026-05-27 | — | — | EP | disclosed |
| US-20260014100-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | YEWSAVIN INC (US) | 2026-01-15 | — | — | US | disclosed |
| EP-4655410-A2 | O-METHYLATION OF PHENOLIC SUBSTANCES VIA FUNGAL O-METHYLTRANSFERASE | Symrise AG (DE) | 2025-12-03 | — | — | EP | disclosed |
| US-12343317-B2 | Compositions and methods for treating bleeding and bleeding disorders | YewSavin, Inc. (US) | 2025-07-01 | — | — | US | disclosed |
| WO-2025017042-A1 | NEW ENZYMES FOR THE MANUFACTURING OF 4'-O-METHYLATED PHENOLIC SUBSTANCES | SYMRISE AG (DE) | 2025-01-23 | — | — | WO | disclosed |
| WO-2024233598-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2024-11-14 | — | — | WO | disclosed |
| WO-2006127539-A1 | USE OF CHALCONES FOR THE TREATMENT OF VIRAL DISORDERS | JOHNSON & JOHNSON CONSUMER COMPANIES, INC. (US) | 2006-11-30 | — | — | WO | disclosed |
| US-20060270614-A1 | Use of chalcones for the treatment of viral disorders | JOHNSON & JOHNSON CONSUMER COMPANIES, INC. | 2006-11-30 | — | — | US | disclosed |
| US-20060135445-A1 | Breast cancer-resistant protein inhibitor | KABUSHIKI KAISHA YAKULT HONSHA (JP) | 2006-06-22 | — | — | US | disclosed |
| WO-2005117849-A1 | DIARYLALKANES AS POTENT INHIBITORS OF BINUCLEAR ENZYMES | UNIGEN PHARMACEUTICALS, INC. (US) | 2005-12-15 | — | — | WO | disclosed |
| US-20050267047-A1 | Diarylalkanes as potent inhibitors of binuclear enzymes | UNIGEN PHARMACEUTICALS, INC. (US) | 2005-12-01 | — | — | US | disclosed |
| EP-1591112-A1 | BREAST CANCER-RESISTANT PROTEIN INHIBITOR | Kabushiki Kaisha Yakult Honsha (JP) | 2005-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267047-A1 | Diarylalkanes as potent inhibitors of binuclear enzymes | TYR, DDT, HAAO | ABCG2 1756/4885MEN1 2314/4885KMT2A 2846/4885 |
| US-20060135445-A1 | Breast cancer-resistant protein inhibitor | ABCC1, BCR, BRCA1 | ABCG2 8/4885MEN1 4488/4885KMT2A 2476/4885 |
| US-20060270614-A1 | Use of chalcones for the treatment of viral disorders | HAVCR2, HMGB3, EIF2AK2 | ABCG2 3800/4885MEN1 3326/4885KMT2A 4014/4885 |
| US-20260014100-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | SERPINC1, F2, F13B | ABCG2 1606/4885MEN1 3367/4885KMT2A 2792/4885 |
| US-12343317-B2 | Compositions and methods for treating bleeding and bleeding disorders | SERPINC1, SERPINE1, SERPINH1 | ABCG2 3622/4885MEN1 2457/4885KMT2A 3188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.